Live Breaking News & Updates on Imerge Trial

Stay updated with breaking news from Imerge trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

Amer Zeidan, MBBS, MHS, presents data from the IMerge phase 3 study on the efficacy of imetelstat in achieving red blood cell transfusion independence across different risk subgroups in patients with lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis-stimulating agents. ....

San Diego , United States , Samer Zeidan , International Prognostic Scoring System , Achieving Red Blood Cell Transfusion Independence , Different Risk Subgroups , Lower Risk Myelodysplastic Syndromes , Erythropoiesis Stimulating Agents , Partnership With , Myelodysplastic Syndrome , Imerge Study , Imerge Trial , Imerge Phase 3 Study , Lower Risk Mds , Lower Risk Myelodysplastic Syndrome , Red Blood Cell Transfusion Independence , Asco 2023 , Imetelstat Efficacy ,

Clinical Implications of Recent Data on New Agents in Lower-Risk MDS

Expert perspectives on the clinical implications of recent clinical trial data on new therapies in lower-risk myelodysplastic syndrome. ....

Future Treatment Strategies , Recent Data , New Agents , Lower Risk Mds , Lower Risk Myelodysplastic Syndrome , Myelodysplastic Syndrome , Clinical Implications , Transfusion Independence , Imerge Trial ,

EMA Validates MAA for Imetelstat for Transfusion-Dependent Anemia in Lower-Risk MDS

The European Medicines Agency has validated the marketing authorization application for the use of imetelstat in the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndrome. ....

Geron Corporation , European Medicines Agency , Transfusion Dependent Anemia In Patients With Lower Risk Myelodysplastic Syndrome , Imerge Trial , Johna Scarlett ,

Data Updates From the IMerge Trial

In the second article of this series, Abdulraheem Yacoub, MD, discusses recent updates from the IMerge clinical trial, which is studying imetelstat in patients with low-risk MDS. ....

United States , Abdulraheem Yacoub , Samer Zeidan , University Of Kansas Cancer Center , American Society Of Clinical Oncology , Clinical Oncology , Annual Meeting , Precision Medicine Perspectives , Lower Risk Myelodysplastic Syndrome , Kansas Cancer Center , Kansas City , Myelodysplastic Syndrome , Imerge Trial , Imerge Results , Transfusion Independence , Intention To Treat , Asco 2023 , Lower Risk Mds , Refractory Anemia , Ring Sideroblasts , Allele Burden , Variant Allele Frequency ,

Dr Zeidan on Imetelstat in Lower-risk MDS

Amer Zeidan, MBBS, discusses topline efficacy findings from the IMerge trial of imetelstat in patients with transfusion-dependent lower-risk myelodysplastic syndrome. ....

Samer Zeidan , Yale Cancer Center , Clinical Trials Office , Protocol Review Committee , Disease Aligned Research Team For Leukemias , Hematology Research Seminar Series , Early Therapeutics Research , Disease Aligned Research Team , Myeloid Malignancies , Executive Committee , Imerge Trial , Patients With Transfusion Dependent Lower Risk Myelodysplastic Syndrome ,